The problem is a solid recovery in sales and EBITDA margin has been the average view of brokers and in my view is currently baked into the share price.
https://www.marketscreener.com/quote...22/financials/
Average analyst view for FY22 was for sales growth of 14%, recovery in EBIT margin to 17.7% and eps of 24 cps and even if they can make those numbers, (which surely must be in doubt now) that's a forward PE of ~ 30 which is exactly the same metrics the shares were trading on in the good old days of mid last decade when it was growing really strongly !
Shares look very fully priced to me and the risk / reward ratio here appears heavily skewed to the downside.